Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
26 January 2024Website:
http://www.arrivent.comNext earnings report:
30 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 03 Jul 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
AVBP Latest News
ArriVent BioPharma, Inc., a company focused on advancing innovative biopharmaceutical therapeutics globally, has appointed John Hohneker, M.D. to its Board of Directors. Dr. Hohneker, who has more than three decades of experience in biopharmaceutical leadership and drug development, currently sits on the Boards of public companies Carisma Therapeutics, Inc. and Curis, Inc., as well as private companies Sonata Therapeutics and Trishula Therapeutics.
ArriVent raised $150 million in an upsized IPO, marking one of the strongest performances for a China-linked IPO in New York over the last two years. The company has licensed global rights, excluding Greater China, to furmonertinib, a highly targeted drug used to treat non-small-cell lung cancer.
What type of business is ArriVent BioPharma Common Stock?
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
What sector is ArriVent BioPharma Common Stock in?
ArriVent BioPharma Common Stock is in the Healthcare sector
What industry is ArriVent BioPharma Common Stock in?
ArriVent BioPharma Common Stock is in the Biotechnology industry
What country is ArriVent BioPharma Common Stock from?
ArriVent BioPharma Common Stock is headquartered in United States
When did ArriVent BioPharma Common Stock go public?
ArriVent BioPharma Common Stock initial public offering (IPO) was on 26 January 2024
What is ArriVent BioPharma Common Stock website?
https://www.arrivent.com
Is ArriVent BioPharma Common Stock in the S&P 500?
No, ArriVent BioPharma Common Stock is not included in the S&P 500 index
Is ArriVent BioPharma Common Stock in the NASDAQ 100?
No, ArriVent BioPharma Common Stock is not included in the NASDAQ 100 index
Is ArriVent BioPharma Common Stock in the Dow Jones?
No, ArriVent BioPharma Common Stock is not included in the Dow Jones index
When does ArriVent BioPharma Common Stock report earnings?
The next expected earnings date for ArriVent BioPharma Common Stock is 30 August 2024